There are 1,226 papers on Charlson Comorbidity Index in aging research: 16 trials and 1,167 observational studies in people, 1 in animals, 32 reviews. The newest story, Nov 14, 2026: “Age and frailty linked to different intensive care outcomes”.
Charlson Comorbidity Index was not clearly linked with mortality in humans (multivariable Cox model adjusting for age and other confounders in elderly AMI patients) (HR = 1.089).
“CCI did not reach statistical significance after adjustment for age and other confounders (HR = 1.089, P = 0.125).”
Humansmultivariable Cox model adjusting for age and other confounders in elderly AMI patientsmedian 40.9 monthsn = 350
Charlson Comorbidity Index was not clearly linked with mortality in humans (COVID-19 diagnosis in nursing home residents) (base AUROC 0.61 (CI: 0.60 to 0.63)).
“The addition of CCI did not improve these predictive performance measures.”
HumansCOVID-19 diagnosis in nursing home residents28 daysn = 4,318
Charlson Comorbidity Index was not clearly linked with mortality in humans (unilateral intertrochanteric fracture undergoing surgical treatment) (survival rates 93.5% vs 86.2%).
“Charlson comorbidity index maybe not the indicator of 2-year mortality in older patients with intertrochanteric fractures.”
Charlson Comorbidity Index is linked with lower survival in humans (ovarian cancer).
“Patients with higher CCI scores had significantly shorter survival, and CCI was identified as an independent prognostic factor in multivariate analysis.”
Charlson Comorbidity Index is linked with lower survival in humans (p<0.001).
“There were linear relationships between Clinical Frailty Scale (CFS) or Charlson Comorbidity Index (CCI) and diminished survival in the pooled data (both p<0.001).”
Charlson Comorbidity Index is linked with lower survival in humans (p < 0.0001).
“Patient survival was significantly different between CCI groups at 1, 3, and 5 years, respectively: 90%, 88%, and 84% for group 1, 88%, 80%, and 72% for group 2, and 87%, 75%, and 63% for group 3 (p < 0.0001).”
Charlson Comorbidity Index is linked with lower overall survival in humans (peripheral T-cell lymphoma) (4.4 months vs 11.9 months (P < .001)).
“Patients with a CCI > 1 had a worse median overall survival (4.4 months) compared with patients with CCI = 0 (11.9 months) and CCI = 1 (8.4 months; P < .001).”
International journal of radiation oncology, biology, physics·
Hospital-associated disability
↔no changein humans1OR 0.98
1 study
Charlson Comorbidity Index was not clearly linked with hospital-associated disability in frail hospitalized older adults (CFS ≥5) (OR 0.98, 95% CI 0.90-1.06).
“and was not observed in the frail group (OR, 0.98; 95% CI, 0.90-1.06).”
Charlson Comorbidity Index was not clearly linked with intrinsic capacity in humans (controlling for age in multivariable analysis) (β = -0.036, 95% CI - 0.142 to 0.070, p = 0.505).
“In multivariable analysis, CCI was not independently associated with preserved IC (β = -0.036, 95% CI - 0.142 to 0.070, p = 0.505)”
Humanscontrolling for age in multivariable analysisfemalesn = 200
Charlson Comorbidity Index was not clearly linked with short-term functional recovery in humans (not statistically significant).
“After adjustment for covariates, specific diagnoses such as Endocrine and Respiratory diseases were strong predictors of recovery, whereas CCI was not statistically significant.”
Charlson Comorbidity Index was not clearly linked with in-hospital mortality in patients admitted to MICU following RRT within 24 hours of admission (p = 0.102).
“In contrast, CCI did not correlate with mortality among patients admitted to MICU (p = 0.102).”
Humansin patients admitted to MICU following RRT within 24 hours of admissionn = 183
COVID-19 was not clearly linked with Charlson Comorbidity Index in humans (geriatric patients readmitted three months after initial admission) (OR 1.12, 95% CI 0.94-1.34).
“The Covid-19 patients did not have worse health after three months compared to the matched controls according to the CCI (odds ratio, OR[95% confidence interval, CI] = 1.12[0.94-1.34])”
Humansgeriatric patients readmitted three months after initial admission
Charlson Comorbidity Index is associated with mortality in humans (sepsis survivors) (Mortality 21%, 38%, 51%, and 67% for Charlson index 0, 1–2, 3–4, and ≥ 5, respectively).
“with comorbidity burden (21%, 38%, 51%, and 67% for Charlson index 0, 1–2, 3–4, and ≥ 5, respectively; p < 0.0001)”
Humanssepsis survivorswithin 2 years after hospital dischargen = 237,075
Charlson Comorbidity Index is associated with mortality in humans Following cement augmentation for osteoporotic vertebral fractures.
“Increasing age, higher Charlson Comorbidity Index (CCI), worse baseline Oswestry Disability Index and EuroQol-5Dimensional index were associated with increased mortality”
HumansFollowing cement augmentation for osteoporotic vertebral fracturesUp to 11 yearsn = 106
Charlson Comorbidity Index is associated with mortality in humans (proximal humerus fractures; multivariable Cox regression) (HR 1.47, 95% CI 1.25–1.73).
“higher CCI was independently associated with increased mortality (HR: 1.47, 95% CI: 1.25–1.73; p<0.001)”
Charlson Comorbidity Index is associated with mortality in humans After ventriculoperitoneal shunting for idiopathic normal pressure hydrocephalus (HR 1.27).
“higher CCI (HR 1.27, p = 0.005) and hospitalization >1 day (HR 3.20, p = 0.001) were independently associated with increased mortality.”
HumansAfter ventriculoperitoneal shunting for idiopathic normal pressure hydrocephalusMedian follow-up 39.1 months61.9% malesn = 452
Charlson Comorbidity Index predicts mortality in humans (colorectal cancer) (AUC 0.686, p = 0.008).
“Significant discrimination was observed only for colorectal cancer after adding the CCI or ECI to the baseline model (CCI AUC 0.686, p = 0.008; ECI AUC 0.682, p = 0.024).”
Charlson Comorbidity Index is linked with a higher risk of mortality in humans (patients with AAAI and indication for elective repair) (HR 1.2, P < 0.001).
“CCI hazard ratio [HR] = 1.2, P < 0.001”
Humanspatients with AAAI and indication for elective repair5-yearn = 424
Charlson Comorbidity Index is associated with in-hospital mortality in humans (first episode of true bacteremia; multivariable analysis) (aOR 1.74, 95% CI 1.10–2.73).
“Immunosuppression, greater comorbidity burden, concomitant COVID-19, and an abdominal source of infection were independently associated with higher odds of in-hospital mortality.”
Humansfirst episode of true bacteremia; multivariable analysisn = 400
Charlson Comorbidity Index predicts in-hospital mortality in patients admitted to CICU following RRT within 24 hours of admission (p = 0.01, R-squared = 0.115).
“CCI was significantly associated with in-hospital mortality in the CICU with a moderate predictive relationship (p = 0.01, R-squared = 0.115)”
Humansin patients admitted to CICU following RRT within 24 hours of admissionn = 61
Charlson Comorbidity Index is linked with a higher risk of in-hospital mortality in humans (undergoing emergency laparotomy with dedicated geriatrician-led perioperative care) (HR 1.38, p = 0.034).
“Each increment in CCI was associated with increased in-hospital (HR 1.38, p = 0.034)”
Humansundergoing emergency laparotomy with dedicated geriatrician-led perioperative caren = 114
Charlson Comorbidity Index predicts in-hospital mortality in humans (hip fracture) (p=0.0001).
“only the presence of cardiac disease (p=0.0001) and the increase in CCI scores (p=0.0001) were found to have a statistically significant increasing effect on mortality”
Charlson Comorbidity Index is linked with a higher risk of in-hospital mortality in humans (invasive mechanical ventilation in the emergency department) (OR 1.19; 95% CI 1.02-1.38).
“Charlson index (OR 1.19; 95% CI 1.02-1.38)”
Humansinvasive mechanical ventilation in the emergency departmentn = 285
Charlson Comorbidity Index is associated with in-hospital mortality in humans (rapid response team activation after major hip surgery) (6.5 [1.8] vs. 5.5 [2.1], p = 0.02).
“those who died displayed higher mean CCI (6.5 [1.8] vs. 5.5 [2.1], p = 0.02)”
Humansrapid response team activation after major hip surgery
Charlson Comorbidity Index is associated with frailty in humans (Receiving maintenance hemodialysis; Charlson Comorbidity Index ≥5; multivariate analysis) (CCI ≥5: OR = 5.086; p = 0.030).
“CCI ≥5 (OR = 5.086; p = 0.030) as independent factors associated with frailty.”
Frailty is associated with Charlson Comorbidity Index in humans (patients with vascular disease; frailty defined by grip strength) (OR 1.86, 95% CI 1.34–2.57).
“Frailty was associated with CCI (odds ratio, 1.86; 95% confidence interval, 1.34-2.57; P = .0002) in the multivariable model.”
Humanspatients with vascular disease; frailty defined by grip strengthn = 311
Charlson Comorbidity Index is associated with frailty in humans (end-stage renal disease; Charlson comorbidity index score ≥5) (OR 2.6, 95% CI 1.0–6.6).
“a Charlson comorbidity index score of ≥5 (OR 2.6, 95 % CI 1.0-6.6) were associated with frailty.”
Humansend-stage renal disease; Charlson comorbidity index score ≥5n = 95
Charlson Comorbidity Index is associated with 1-year mortality in humans (fragility fracture of the pelvis) (adjusted odds ratio 2.55, 95% confidence interval 1.43-7.21).
“the updated Charlson Comorbidity Index score (adjusted odds ratio 2.55, 95% confidence interval 1.43-7.21; p”
Humansfragility fracture of the pelvis1-yearn = 46
Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association·
Charlson Comorbidity Index is associated with 1-year mortality in humans following revision total hip arthroplasty for periprosthetic hip fractures (1.70 ± 1.49 vs. 0.80 ± 1.57; p = 0.02).
“Patient- (higher Charlson Comorbidity Index [CCI] 1.70 ± 1.49 vs. 0.80 ± 1.57, p = 0.02) and surgical- (dislocation post-rTHA - 30%, [OR 4.8] p = 0.03) factors were associated with 1-year mortality.”
Humansfollowing revision total hip arthroplasty for periprosthetic hip fractures1 year62% femalesn = 96
Charlson Comorbidity Index is linked with a higher risk of 1-year mortality in humans (undergoing emergency laparotomy with dedicated geriatrician-led perioperative care) (HR 1.39, p = 0.006).
“and 1-year (HR 1.39, p = 0.006) mortality”
Humansundergoing emergency laparotomy with dedicated geriatrician-led perioperative caren = 114
Charlson Comorbidity Index is associated with overall survival in humans (primary breast cancer treated with upfront surgery) (p = 0.012).
“worse OS was associated with older age or more comorbidities as measured by the Charlson Comorbidity Index (CCI) (p < 0.001 and p = 0.012, respectively).”
Humansprimary breast cancer treated with upfront surgeryfemalesn = 553
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·
Charlson Comorbidity Index predicts overall survival in humans (non-metastatic prostate cancer) (c-index = 0.763).
“Regarding the prediction of 5-year overall survival, CCI (c-index = 0.763) slightly higher predictive performance than ECI (0.758), NCI (0.755), and C3 (0.754).”
Among older intensive care patients, 50.2% of kidney injury survivors recovered by discharge; frailty and other illnesses were linked to lower recovery.Among older intensive care patients, 50.2% of kidney injury survivors recovered by discharge; frailty and other illnesses were linked to lower recovery.
In a randomized trial, 600 hospitalized adults with swallowing difficulties received one of two care programs; most differences were no longer evident at six months.In a randomized trial, 600 hospitalized adults with swallowing difficulties received one of two care programs; most differences were no longer evident at six months.
Accepted, not yet published: randomized trial · 600 peopleInterventions
Who was studied600 hospitalized older adults with oropharyngeal dysphagia, six months
What changedQuality of life was better with enhanced swallowing care than with the minimal program at one month
The catchRecovery after hospitalization could explain improvements shared by both care programs